News Releases
- July 18, 2023Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
- June 27, 2023Annovis Bio Announces the Filing of a Groundbreaking Patent
- June 20, 2023Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
25
Notification filed by a National Securities Exchange to Report the Removal from listing and registration of matured , redeemed or retired securities
Nov 26, 2021
E-mail Alerts
Back to Top